Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

The debt refinancing is expected to help the company in the impending spinoff of its eye-care company, Bausch + Lomb. This drugmaker is expected to post quarterly earnings of $1.05 per share in ...

The review of the contact lens solutions is tabulated in Table 1. Of the 16 currently available solutions for soft lenses and the five combined soft and rigid solutions, none advised rinsing of ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

Harris said she would continue to work on a two-state solution “around the clock.” “In that solution there must be security for the Israeli people and Israel and in equal measure for the ...

As part of the deal, Bausch + Lomb will help scale commercialization of Trukera’s ScoutPro Osmolarity System, a device that measures tear osmolarity, or the salt content of a person’s tears, to help ...